Fluoxetine, a selective serotonin-uptake inhibitor, has been shown to be effective in the treatment of depression. A series of studies found fluoxetine to be more effective than placebo and to be associated with equivalent efficacy to standard reference tricyclic antidepressants (Stark & Hardison, 1985; Feighner & Cohn, 1985). The selection of a dosage regime for fluoxetine in these studies was based on the information gathered from open dose-ranging investigations. In these studies, treatment starts with one dose level, which is then increased as indicated in the protocol or until increased doses are not tolerated due to side-effects. One of the weaknesses in this method of choosing the likely standard dose of a new antidepressant lies in the inherent bias towards the selection of the higher dose levels. This is particularly true for drugs which are well tolerated.
No takes yet. Share an insight, caveat, or question.
Altamura et al. (1988) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: